Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for Uncomplicated falciparum Malaria in Equatorial Guinea (Central Africa)

Objectives. The objectives of the study were (i) to evaluate the efficacy of combination drugs, such as artesunate + sulphadoxine-pyrimethamine (AS + SP) and amodiaquine + sulphadoxine-pyripethamine (AQ + SP) in treatment of uncomplicated falciparum malaria (ii) to differentiate recrudescence from reinfection by analysing msp-1 and msp-2 genes of Plasmodium falciparum in treatment failure cases. Methods. We carried out an in vivo study in the year 2005 in 206 children between 6 to 59 months age groups. Of the 206, 120 received AQ + SP, and 86 received AS + SP. A clinical and parasitological followup during 14 days was undertaken. Finger-prick blood sample from each patient was taken on Whatman filter paper (no. 3) on days 0, 7, 14 and also the day when the parasite and symptoms reappeared for PCR analysis. Results. Late treatment failure was observed in 3.5% (4/114) with AQ + SP, and 2.5% (2/79) with AS + SP. The success rate was 96.5% with AQ + SP and 97.5% with AS + SP. No deaths and severe reactions were recorded. Out of the 6 treatment failure cases, one was reinfection as observed by PCR analysis of msp-1 and msp-2 genes on day 14. Discussion. Both the combinations found to be efficacious and safe and could be used as a first-line treatment for uncomplicated falciparum malaria in Equatorial Guinea

Clinical Study Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for Uncomplicated falciparum Malaria in Equatorial Guinea (Central Africa)

Recommended by Sukla Biswas Objectives. The objectives of the study were (i) to evaluate the efficacy of combination drugs, such as artesunate + sulphadoxinepyrimethamine (AS + SP) and amodiaquine + sulphadoxine-pyripethamine (AQ + SP) in treatment of uncomplicated falciparum malaria (ii) to differentiate recrudescence from reinfection by analysing msp-1 and msp-2 genes of Plasmodium falciparum in treatment failure cases. Methods. We carried out an in vivo study in the year 2005 in 206 children between 6 to 59 months age groups. Of the 206, 120 received AQ + SP, and 86 received AS + SP. A clinical and parasitological followup during 14 days was undertaken. Finger-prick blood sample from each patient was taken on Whatman filter paper (no. 3) on days 0, 7, 14 and also the day when the parasite and symptoms reappeared for PCR analysis. Results. Late treatment failure was observed in 3.5% (4/114) with AQ + SP, and 2.5% (2/79) with AS + SP. The success rate was 96.5% with AQ + SP and 97.5% with AS + SP. No deaths and severe reactions were recorded. Out of the 6 treatment failure cases, one was reinfection as observed by PCR analysis of msp-1 and msp-2 genes on day 14. Discussion. Both the combinations found to be efficacious and safe and could be used as a first-line treatment for uncomplicated falciparum malaria in Equatorial Guinea

Implementación y creación de escenarios de pruebas con el NAC PacketFence

En la actualidad, está en constante aumento los ataques cibernéticos y las amenazas a las infraestructuras de red, esto hace que cada vez más la seguridad de las redes sea un tema fundamental e importante para las empresas. Este trabajo fin de master se centra en encontrar una posible solución de seguridad para este tipo de casos. La solución de seguridad elegida es el NAC de packetfence, un sistema de control de acceso a la red que permite crear roles y políticas para la autenticación del usuario y detección de posibles amenazas en la red. Este trabajo se ha ejecutado en la plataforma google cloud, y he utilizado EVE-NG como entorno de virtualización para integrar los dispositivos con los que he trabajado como los Router, Switch, máquinas virtuales. En primer lugar, he implementado el NAC de packetfence en una máquina virtual Debían y he configurado los pasos necesarios previos para que funcione correctamente, luego he procedido a integrar este sistema de control en una red corporativa. En segundo lugar, he integrado el controlador de dominio Active Directory en una LAN para crear los usuarios y grupos, y que packetfence filtre esos usuarios y los autentique según las reglas establecidas. Los protocolos de autenticación y autorización han sido RADIUS, IEEE 802.1X, MAB y EAP-PEAP. Por otro lado, está una segunda LAN que he configurado en una segunda interface de packetfence para realizar otro tipo de escenario de prueba. Finalmente, he configurado los dispositivos para poder realizar los dos escenarios de pruebas, he documentado los resultados y los problemas encontrados durante la implementación